Every material Form 8-K Cigna filed with the SEC in 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
The Cigna Group reported third-quarter 2026 total revenues of $73.7 billion and shareholders' net income of $1.4 billion, or $5.47 per share. Driven by strong segment execution, the company raised its full-year 2026 adjusted income from operations outlook to at least $30.60 per share.
Total revenues for the third quarter of 2026 increased 6% year-over-year to $73.7 billion.
Shareholders' net income for the third quarter of 2026 was $1.4 billion, or $5.47 per share.
Full-year 2026 adjusted income from operations outlook was raised to at least $30.60 per share.
The company repurchased 1.8 million shares of common stock for approximately $500 million through November 4, 2026.
Cigna Group said director Donna F. Zarcone informed the Board on October 6, 2026, that she will retire effective December 31, 2026. The company stated her retirement is not the result of any disagreement with the company.
Donna F. Zarcone notified the Board of her retirement on October 6, 2026.
Retirement takes effect December 31, 2026.
The company said the retirement is not due to any disagreement with Cigna.
Filing was signed by Andrea Nelson, General Counsel and Corporate Secretary, on October 9, 2026.
The Cigna Group reported second quarter 2026 results, with total revenues up 7% to $71.7 billion and shareholders' net income of $1.7 billion, or $6.29 per share, versus $5.71 a year earlier. Adjusted income from operations rose 6% to $2.1 billion, or $7.78 per share, and the company raised its full-year 2026 adjusted per-share outlook to at least $30.45, an increase of $0.10. For shareholders, the higher outlook and improved headline profit are offset in part by a sharp drop in Pharmacy Benefit Services profit.
Total revenues rose 7% to $71.7 billion; shareholders' net income was $1.7 billion, or $6.29 per share, compared with $1.5 billion, or $5.71 per share, in Q2 2025.
Adjusted income from operations was $2.1 billion, or $7.78 per share, compared with $7.20 per share in Q2 2025.
Full-year 2026 adjusted income from operations outlook increased to at least $30.45 per share, up $0.10 from the prior projection.
Pharmacy Benefit Services adjusted pre-tax income fell 27% year over year, while Cigna Healthcare adjusted pre-tax income rose 17%.
The Cigna Group reported first quarter 2026 results on April 30, 2026, with total revenues up 5% to $68.5 billion and shareholders' net income of $1.7 billion, or $6.26 per share, versus $1.3 billion, or $4.85 per share, a year earlier. It raised its full-year 2026 adjusted income from operations outlook to at least $30.35 per share, up $0.10, which points to higher expected per-share earnings for shareholders. Within Evernorth, Pharmacy Benefit Services adjusted pre-tax income fell 28%, while Cigna Healthcare adjusted pre-tax income rose 18%.
Total revenues rose 5% to $68.5 billion for the quarter ended March 31, 2026.
Shareholders' net income was $1.7 billion, or $6.26 per share, versus $1.3 billion, or $4.85 per share, in Q1 2025.
Adjusted income from operations was $2.1 billion, or $7.79 per share, versus $6.74 per share in Q1 2025.
2026 adjusted income from operations outlook is at least $30.35 per share, a $0.10 increase; Pharmacy Benefit Services adjusted pre-tax income fell 28%.
The Cigna Group said Brian Evanko, its president and chief operating officer, will become chief executive on July 1, 2026, succeeding David Cordani, who retires as CEO and becomes executive chair. Evanko also joins the board effective April 1, 2026, and the company reaffirmed its 2026 outlook, including adjusted income from operations of at least $30.25 per share. For shareholders, the filing sets a planned leadership transition and leaves the 2026 financial outlook unchanged.
Brian Evanko, 49, becomes CEO on July 1, 2026; he has been president and chief operating officer since March 2025 and was chief financial officer from January 2021 to January 2024
David Cordani retires as CEO on July 1, 2026 and becomes executive chair; Eric Wiseman becomes Chair of the Corporate Governance Committee as Eric Foss becomes lead independent director on April 1, 2026
Evanko's annual base salary will be $1.3 million and his long-term incentive target $15.1 million, effective July 1, 2026
Reaffirmed 2026 outlook: adjusted income from operations of at least $30.25 per share, Evernorth pre-tax adjusted income of at least $6.9 billion, and Cigna Healthcare pre-tax adjusted income of at least $4.5 billion
Cigna reported full-year 2025 total revenues of $274.9 billion, up 11%, and shareholders' net income of $6.0 billion, or $22.18 per share, compared with $3.4 billion in 2024. Fourth-quarter net income fell to $1.2 billion from $1.4 billion, and the company projected 2026 adjusted income from operations of at least $7.950 billion, or at least $30.25 per share, while raising its quarterly dividend to $1.56 per share.
Full-year 2025 adjusted income from operations rose 4% to $8.0 billion, or $29.84 per share, from $7.7 billion, or $27.33 per share, in 2024.
Fourth-quarter 2025 shareholders' net income was $1.2 billion, or $4.64 per share, down from $1.4 billion, or $5.13 per share, in fourth-quarter 2024.
2026 outlook calls for adjusted revenues of approximately $280.0 billion and adjusted income from operations of at least $7.950 billion, or at least $30.25 per share.
Board declared a quarterly dividend of $1.56 per share, up from $1.51, payable March 19, 2026 to holders of record as of March 5, 2026.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Cigna filing is on SEC EDGAR ↗. 8-K briefs of other companies →